Patience Assistance Programmes: Achieving Stakeholder Buy in
Patient Assistance Programmes (PAPs) help US patients financially and improve compliance, adherence and outcomes – what’s not to like? But many payers are sceptical, seeing PAPs as a cynical ploy by Pharma to buy market share and support drug prices.
This report explores the patient benefits, operational challenges and attitudes to, and the future for, PAPs through the eyes of payer and pharma experts. With the number of PAPs growing rapidly, the report uncovers what Pharma can do to positively engage all stakeholders. Reasons to Purchase
Leading Pharma and Payer Experts Answer Key Questions:
Targeting support: Where should PAP money be targetedClinical benefits: What are the clinical benefits and clinician experience of PAPs?
Too complex: PAPs can be complex and challenging for patients and many do not engage – what role might technology play is streamlining this area?
Insurers role: To what extent are health insurers fuelling the need and growth of PAPs through their behaviour and policies?
Barriers: How might Pharma work with payers to develop PAP’s that meet both parties’ needs?
Obamacare: Why has the Patient Protection and Affordable Care Act not killed off the need for PAPs?
Patient Groups: What advantages could Pharma gain by closer collaboration with patient groups in the design and communication of PAPs?
Key Topics Explored
Drug price control proposals are vote winners and both Hilary Clinton and Donald Trump have indicated support. But is this really a likelihood?
Collaboration not confrontation is the way forward and sharing data from PAPs with payers could overcome resistance by demonstrating the benefits of compliance and better health outcomes.
Many companies now see PAPs as a key part of their commercial strategy and most products are now launched with a PAP
The free-of-charge PAPs are seen by patients and clinicians as part of pharmaceutical companies’ social responsibility activities and generate positive PR.
Online pharmacies could scupper some PAP initiatives. How concerned should you be?
This report represents a wide range of experience and views with contributions from:
Four US payers
Two pharmaceutical industry representatives
Nathan White, Global Practice Lead, Access Pathways and Outcomes, ApotheCom, a medical communications agency.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.